| 摘要 |
<p>The invention provides a method of treatment of a chronic inflammatory disease (such as rheumatoid arthritis) in a patient, the method comprising the administration to the patient of a compound that selectively inhibits Tck cells. Preferably, said compound selectively inhibits Tck cell-induced release of one or more pro-inflammatory cytokines from monocytes. Advantageously, said compound inhibits NF-λB. Conveniently, said compound activates PI3 kinase. The invention further provides a method of identifying a compound with efficacy in the treatment of a chronic inflammatory disease comprising the step of testing said compound for an ability to selectively inhibit Tck cells. Preferably, said method of identifying a compound with efficacy in the treatment of a chronic inflammatory disease comprises the step of testing said compound for an ability to selectively inhibit Tck cell-induced release of one or more pro-inflammatory cytokines from monocytes. Conveniently, the pro-inflammatory cytokine is tumour necrosis factor α (TNFα). The invention further provides compounds identifiable or identified by said methods and the use of said compounds in medicine. Additionally, the invention provides an antibody-like molecule with specificity for Tck cells, and compounds comprising said antibody-like molecule and a cytotoxic moiety.</p> |
